David A. Siegel Alnylam Pharmaceuticals, Inc. Transaction History
Two Sigma Advisers, LP
- $41.3 Billion
- Q3 2024
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Alnylam Pharmaceuticals, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 103,100 shares of ALNY stock, worth $24.2 Million. This represents 0.07% of its overall portfolio holdings.
Number of Shares
103,100
Previous 258,700
60.15%
Holding current value
$24.2 Million
Previous $62.9 Million
54.89%
% of portfolio
0.07%
Previous 0.14%
Shares
23 transactions
Others Institutions Holding ALNY
# of Institutions
644Shares Held
109MCall Options Held
1.28MPut Options Held
1.21M-
Capital World Investors Los Angeles, CA16.5MShares$3.87 Billion0.73% of portfolio
-
Vanguard Group Inc Valley Forge, PA12.6MShares$2.96 Billion0.06% of portfolio
-
Black Rock Inc. New York, NY9.55MShares$2.24 Billion0.05% of portfolio
-
Capital Research Global Investors Los Angeles, CA5.24MShares$1.23 Billion0.31% of portfolio
-
Wellington Management Group LLP Boston, MA4.95MShares$1.16 Billion0.24% of portfolio
About ALNYLAM PHARMACEUTICALS, INC.
- Ticker ALNY
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 123,028,000
- Market Cap $28.8B
- Description
- Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...